Search Results - technology+classifications+%3e+therapeutic+modalities+%3e+dendrimers+%26+polymers

20 Results

Sort By:

Value PropositionVersatile immunotherapy platform with the ability to specifically target antigen presenting cells (APCs) ) following systemic delivery and without requiring targeting ligands to improve treatment efficacy. Flexibility to modulate the immune system through activation or inducing tolerance.Useful as a preventative strategy or therapeutic...

Published: 5/10/2024 | Inventor(s): Jordan Green, Elana Ben-Akiva, Johan Karlsson, Stephany Tzeng, Kelly Rhodes, Sarah Neshat

Keywords(s):

Category(s): Clinical and Disease Specializations > Autoimmunity, Clinical and Disease Specializations > Immunology, Technology Classifications > Medical Devices > Therapeutic Devices, Technology Classifications > Therapeutic Modalities > Dendrimers & Polymers, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities > Vaccines

PtCu Nanozyme Scavenging ROS for Prevention of Pathologic α-Synuclein Transmission

Description: Unmet Need Parkinson’s disease (PD) is the second most common neurodegenerative disorder characterized with misfolded α-synuclein (α-syn) accumulation in Lewy bodies (LB). Although some α-syn mutations have been associated with familial PD, the majority cases are sporadic with unknown etiology. Tremendous efforts have been made to develop...

Published: 5/10/2024 | Inventor(s): Xiaobo Mao, Weiwei He, Yuqing Liu

Keywords(s):

Category(s): Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Neurology > Neurodegeneration, Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Dendrimers & Polymers

Biopolymer Encapsulation Increases the Bioavailability and Efficacy of D-PDMP in Interfering with Atherosclerosis and Cardiac Hypertrophy in apoE-/- Transgenic Mice

INVENTION NOVELTYA novel glycolipid inhibitor anti-atherosclerosis drug compound able to enhancegastro-intestinal absorption and residence time to reduce and ameliorateeffects of arteriosclerosis VALUE PROPOSITIONDespite great success of statins (cholesterol reducing agents), little is known aboutother molecules such as glycolipids that also rise with...

Published: 5/9/2024 | Inventor(s): Subroto Chatterjee

Keywords(s): Antagonists/Inhibitors, Cardiovascular Diseases, Disease Indication, Drug Delivery Vehicle, Non-novel, Off-the-shelf, Polymers, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Cardiovascular, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Dendrimers & Polymers, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities

Bioreducible Poly(beta-amino ester)s for siRNA Delivery

C12218: Efficient Delivery Vehicle for Controlled Gene Knockdown Novelty: This technology comprises the use of bioreducible polymer based nanoparticle system that can release siRNA cargo to the cytoplasm of cells to knockdown target gene expression in tissues. Value Proposition: Gene therapy is a developing medical field and there is a need for...

Published: 5/9/2024 | Inventor(s): Kristen Kozielski, Stephany Tzeng, Jordan Green

Keywords(s): Biologics, Brain Cancer, Cancers, Cell Therapy, Disease Indication, Drug Delivery Vehicle, Glioma, Nucleic Acid, Polymers, Single, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Gene Therapies, Technology Classifications > Therapeutic Modalities > Cell Therapies, Technology Classifications > Therapeutic Modalities > Dendrimers & Polymers, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Brain Cancer, Clinical and Disease Specializations > Oncology > Glioma

Inhalable Supramolecular Therapeutics to Treat Lung Diseases

Unmet NeedThe current global market for respiratory drugs is expected to increase from $30.9 billion in 2016 to $41.3 billion in 2023. While many aerosol therapeutics are used to treat lung diseases such as chronic obstructive pulmonary disease, asthma, and cystic fibrosis, administration of drugs selectively to the lungs remains challenging. The nature...

Published: 5/9/2024 | Inventor(s): Honggang Cui, Caleb Anderson

Keywords(s): Disease Indication, Drug Delivery Mechanism, Drug Delivery Vehicle, Drug Delivery Vehicle Synthesis Method, Lung Disorders, Polymers, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations > Respiratory Diseases, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities > Dendrimers & Polymers

Compositions and Method for Production of Size-Controlled Ternary Nanoparticles for Sustained Release of Peptide Therapeutics

Unmet NeedType 2 diabetes (T2D) contributes to 90% of all cases of diabetes and represents a critical global public health problem. T2D specifically affects glucose metabolism and those with the disease either do not produce enough insulin or do not respond properly to insulin signaling to maintain normal levels of glucose in the blood. Several serious...

Published: 5/9/2024 | Inventor(s): Hai-Quan Mao, Zhiyu He, Yizong Hu, Yongming Chen, Lixin Liu

Keywords(s): Biologics, Drug Delivery Vehicle, Drug Delivery Vehicle Synthesis Method, Nanoparticles, Peptide, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities > Dendrimers & Polymers

Organoborane Strategy for Polymers Bearing Lactone, Ester, and Alcohol Functionality

C16077 Marketing Summary Unmet NeedAlthough vinyl alcohol-methyl methacrylate (VA-MMA) copolymers have intriguing functionally-rich structure that could impact a polymer’s properties, they are synthetically inaccessible from vinyl acetate (VAc), the traditional precursor to polyvinyl alcohol (PVA). VAc is poorly compatible with early transition metal...

Published: 5/9/2024 | Inventor(s): Rebekka Klausen, Yuyang Ji

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities > Dendrimers & Polymers, Technology Classifications > Industrial Tech > Materials

Polymer of Prodrug Methods for Sustained Release of Antivirals for Treatment or Prevention of HIV

Unmet Need:Human immunodeficiency virus (HIV) infection and acquired immune deficiency syndrome (AIDS) are amongst the most serious and challenging health problems in the world. There are nearly 37 million people worldwide living with HIV/AIDS and approximately 1 million AIDS-related deaths have occurred in 2017 alone - about 5,000 new infections per...

Published: 5/9/2024 | Inventor(s): Caren Freel Meyers, Steven Rannard, Andrew Owen, Kartik Temburnikar, Lauren Coco, Stephanie Henriquez, Faye Hern, Chung Liu, Anika Shakil, Megan Neary

Keywords(s): Disease Indication, HIV, Infectious Diseases, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutic Substance Synthesis Method, Therapeutics

Category(s): Clinical and Disease Specializations > Infectious Diseases > HIV/AIDS, Technology Classifications > Therapeutic Modalities > Dendrimers & Polymers, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms

A Novel Method to Efficiently Synthesize a Biodegradable Dextran to Use as an Efficient Cationic Nanopolymer Carrier for siRNA Delivery

Unmet NeedIn theory, RNA interference (RNAi) can be used to decrease expression of any gene driving a disease or pathology, but has seen limited clinical usage as gene therapy due to technical issues, i.e., small interfering RNA (siRNA) cannot enter cells efficiently due to their weight and charge. As such, a carrier molecule is needed to bring siRNA...

Published: 5/9/2024 | Inventor(s): Zaver Bhujwalla, Zhihang Chen

Keywords(s): Biologics, Cancers, Disease Indication, Drug Delivery Vehicle, Nucleic Acid, Polymers, Therapeutic Matter, Therapeutic Method, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities > Dendrimers & Polymers, Technology Classifications > Research Tools > Nucleic Acids

Polymeric Nanoparticle Compositions for Encapsulation and Sustained Release of Protein Therapeutics and Methods for Scalable Production of the Same

Unmet NeedProtein therapeutics are used for a variety of medical treatments, such as cancer, infectious disease, hemophilia, anima, etc. The global market for protein drugs reached $174.7 billion in 2015. Therapeutic proteins support targeted therapeutic processes by compensating the deficiency of an essential protein. To successfully administer protein...

Published: 5/9/2024 | Inventor(s): Hai-Quan Mao, Sashank Reddy, Xiyu Ke, Chenhu Qiu, Daniel Lucena Domingues, Gregory Howard

Keywords(s): Drug Delivery Vehicle, Drug Delivery Vehicle Synthesis Method, Nanoparticles, Therapeutic Matter, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Dendrimers & Polymers

1 2